Patent classifications
A61L2300/42
Biological component adhesion-suppressing material
A biological component adhesion-suppressing material includes a substrate provided with a functional layer having, fixed on a surface thereof that comes into contact with a biological component, a polymer including a saturated aliphatic monocarboxylic acid vinyl ester unit, wherein: when compositional analysis is performed on the surface of the functional layer using a TOF-SIMS device, the number of carbon atoms in an aliphatic chain representing an ion signal detected for saturated aliphatic carboxylic acid is 2-20; and an XPS measurement taken of the surface of the functional layer shows a peak derived from an ester group.
COATINGS FOR IMPLANTABLE DEVICES
Intraocular pressure sensors, systems, and methods of use. Implantable intraocular pressure sensing devices that are hermetically sealed and adapted to wirelessly communicate with an external device. The implantable devices can include a hermetically sealed housing, the hermetically sealed housing including therein: an antenna in electrical communication with a rechargeable power source, the rechargeable power source in electrical communication with an ASIC, and the ASIC in electrical communication with a pressure sensor.
COMPOSITIONS AND METHODS FOR PREPARING AND USING NON-IMMUNOGENIC FAST ANNEALING MICROPOROUS ANNEALED PARTICLE HYDROGELS
Non-degradable, non-immunogenic microporous hydrogel compositions are provided. Such hydrogel compositions consist of flowable hydrogel particles comprising a bioinert polymeric backbone, including for example a poly(ethylene glycol)(PEG)-based polymeric backbone, an annealing component comprising a physiologically-stable, radically polymerizable alkene, including for example methacrylamide, and a heparin compound. Methods of treating glottic incompetence and/or providing laryngeal reconstruction are also provided. Such methods consist of providing a subject suffering from glottic incompetence and/or in need of laryngeal reconstruction, and administering a non-degradable, non-immunogenic microporous hydrogel composition disclosed herein.
A Degradable Vascular Stent Capable Of Avoiding Late Restenosis
The present invention relates to a degradable vascular stent capable of avoiding late restenosis, comprising a base region formed by a polylactic acid based polymer; at least one storage region in which an active agent is stored; and an outer layer of a drug sustained release coating covered on the base region and/or the storage region. Before the mass of the polylactic acid based polymer is decreased by 10-20%, the active agent is retained in structural units of the polylactic acid based polymer. After the mass of the polylactic acid based polymer is decreased by 10-20%, the active agent is released from the storage region. The base region provides a supporting capacity for ensuring patency of blood vessels; the drug sustained release coating is used for drug release in an early stage; and the active agent only works in late degradation of the stent to avoid late restenosis.
Prosthetic tissue valves
A prosthetic valve comprising a conical shaped ribbon structure comprising an extracellular matrix (ECM) composition. The ribbon structure comprises a plurality of elongated ribbon members that are positioned proximate each other in a joined relationship, wherein the ribbon members are positioned adjacent each other and form a plurality of fluid flow modulating regions that open when fluid flow through the valve exhibits a negative flow pressure and open when fluid flow through the valve exhibits a positive flow pressure.
Graft material having selectively advanced permeability structure and method
A laser is used to form openings within a graft material to selectively enhance permeability of a prosthesis for tissue integration therein. A feature of utilizing a laser to create the openings for tissue integration builds from its tunability. More particularly, the laser precisely places openings in any pattern and location, and on any textile that forms the graft material. Further, the power and focus of the laser is precisely adjusted to control the diameter and shape of the openings. All parameters of the openings can be controlled at will, allowing for the opportunity to selectively enhance and optimize the permeability of the graft material in a vessel.
Variable permeability layered structure and method
The techniques of this disclosure generally relate to a variable permeability layered prosthesis including an impermeable outer layer and a permeable inner layer. The impermeable outer layer is well suited to seal a dissection opening of a dissection. The permeable inner layer allows fluid to enter into a dead space between the impermeable outer layer and the permeable inner layer. The fluid in the dead space coagulates in the dead space providing a media for tissue growth into the prosthesis. The ability of tissue to integrate into the prosthesis provides biological fixation of the prosthesis in vessels and prevents endoleaks and migration of the prosthesis.
MEDICAL DEVICES FOR CONTINUOUS DELIVERY OF THERAPEUTIC AGENTS
The present invention relates to compositions and methods to provide continuous and controlled release of therapeutic agent(s) during a procedure such as an interventional vascular procedure, e.g., to reduce acute and chronic complications and improve outcomes. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Immobilised biological entities
There is provided inter alia an anticoagulant surface which surface has covalently bound thereto a plurality of fragments of heparin, wherein said fragments consist of 5-18 saccharide units and at least some of said plurality of fragments comprise polysaccharide sequence A, which surface catalyses the inhibition of FIIa and FXa by AT.
Coatings containing multiple drugs
A method for depositing a coating comprising a polymer and at least two pharmaceutical agents on a substrate, comprising the following steps: providing a stent framework; depositing on said stent framework a first layer comprising a first pharmaceutical agent; depositing a second layer comprising a second pharmaceutical agent; Wherein said first and second pharmaceutical agents are selected from two different classes of pharmaceutical agents.